Jacobs Levy Equity Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Jacobs Levy Equity Management’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-110	Closed	-$27K	–	1126
2018 Q1	$27K	Hold	110	–	–	﹤0.01%	987
2017 Q4	$31K	Sell	110 -158	-59%	-$60.3K	﹤0.01%	972
2017 Q3	$108K	Hold	268	–	–	﹤0.01%	916
2017 Q2	$159K	Hold	268	–	–	﹤0.01%	867
2017 Q1	$165K	Sell	268 -508	-65%	-$181K	﹤0.01%	816
2016 Q4	$157K	Buy	+776	New	+$176K	﹤0.01%	855

Other funds holding VYNT

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diker Management New York $112M AUM 59.78% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Jacobs Levy Equity Management's VYNT Position: Q2 2018 in Review

Jacobs Levy Equity Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2018, closing a stake of 110 shares — an estimated $27K sold.

Jacobs Levy Equity Management first reported a position in VYNT in Q4 2016 and held it in 6 quarters. The position peaked at $165K in Q1 2017. 23 funds tracked by Wall St. Rank hold VYNT as of Q2 2018.

Jacobs Levy Equity Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 110 Vyant Bio, Inc. Common Stock shares in Q2 2018, an estimated $27K.
Jacobs Levy Equity Management first reported a position in Vyant Bio, Inc. Common Stock in Q4 2016 and held it in 6 quarters.
Jacobs Levy Equity Management's Vyant Bio, Inc. Common Stock position peaked at $165K in Q1 2017.
23 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2018, filed 14 Aug 2018.